Biojector 2000 Data Presented in Vical's Pandemic Influenza DNA Vaccine Human TrialPORTLAND, Ore.--(BUSINESS WIRE)--Jul 17, 2008 - Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy systems, today announced that the Biojector(R) 2000 (B2000) was used in Vical Inc.'s (Vical) first Phase 1 human trial of H5N1 pandemic influenza DNA vaccines formulated with Vical's Vaxfectin(R) adjuvant. Data were presented today by Vical at the IBC Life Sciences Next Generation Vaccines conference held in Maryland.
The double-blind, placebo-controlled, dose-escalation trial was conducted in approximately 100 healthy volunteers age 18 to 45 at three U.S. clinical sites. The trial was designed to assess safety and immunogenicity following intramuscular vaccination with needle and syringe or with the B2000 needle-free injection therapy system in different cohorts, and to evaluate monovalent and trivalent Vaxfectin(R)-formulated DNA vaccines at various doses.
"The successfully completed study was partially designed to demonstrate the feasibility of the B2000 system to deliver Vaxfectin(R)-formulated H5N1 DNA vaccines," said Dr. Richard Stout, Bioject's Executive Vice President and Chief Medical Officer. "Our work with Vical over the past several years, and the successes shown in pre-clinical testing, has allowed us to move forward together with other vaccine studies. We look forward to working with them in the future."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding potential benefits provided by our NFIT product to the Vical pDNA vaccine. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, uncertainties related to the effect our product will have on this specific vaccine. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
For more information about Bioject, visit www.bioject.com.
Bioject Medical Technologies Inc.
Ralph Makar, 503-692-8001 ext. 4137
President and CEO
Dr. Richard Stout, 503-692-8001 ext. 4130
Executive Vice President and Chief Medical Officer
Posted: July 2008